Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan

Shock

Volumn 7, Issue 5, 1997, Pages 364-370

  Wanecek, Michael ^a   Oldner, Anders ^a   Rudehill, Anders ^a   Sollevi, Alf ^a   Alving, Kjell ^b   Weitzberg, Eddie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; HEMOGLOBIN; LACTIC ACID; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DISORDERS OF ACID BASE BALANCE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; METABOLISM; OXYGEN CONSUMPTION; PULMONARY HYPERTENSION; SEPTIC SHOCK; SWINE; TREATMENT OUTCOME;

ACID-BASE IMBALANCE; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; FEMALE; HEMOGLOBINS; HYPERTENSION, PULMONARY; LACTIC ACID; MALE; OXYGEN CONSUMPTION; RECEPTORS, ENDOTHELIN; SHOCK, SEPTIC; SULFONAMIDES; SWINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031136906     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199705000-00009     Document Type: Article

References (40)

1. Opal S, Clinical trials of novel therapeutic agents: Why did they fail? In Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Heidelberg, Germany: Springer-Verlag, 1995, pp 425-436.
2. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988.
3. Ehrenreich H, Anderson R, Fox C, et al: Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med 172:1741-1748, 1990.
4. Rubanyi G, Polokoff M: Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46:325-415, 1994.
5. Opgenorth TJ: Endothelin receptor antagonism. Adv Pharmacol 33:1-65, 1995.
6. Ahlborg G, Weitzberg E, Lundberg JM: Circulating endothelin-1 reduces splanchnic and renal blood flow and splanchnic glucose production in humans. J Appl Physiol 79:141-145, 1995.
7. Aral H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730-732, 1990.
8. Sakurai T, Yanagisawa M, Takuwa Y, et al: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732-735, 1990.
9. De Nucci G, Thomas R, d'Orleans-Juste P: Presser effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85:9797-9800, 1988.
10. B receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873, 1992.
11. Clozel M: Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235, 1994.
12. Weitzberg E, Rudehill A, Lundberg J: Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock. Eur J Pharmacol 233:85-94, 1993.
13. Weitzberg E, Lundberg J, Rudehill A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 33:222-227, 1991.
14. Pittet J, Morel D, Hemsén A, et al: Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 213:261-264, 1991.
15. Sugiura M, Inagami T, Kon V: Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun 161:1220-1227, 1989.
16. Han J, Windsor A, Drenning D, et al: Release of endothelin in relation to TNF-α in porcine Pseudomonas aeruginosa-induced septic shock. Shock 1:343-346, 1994.
17. Marsdeen P, Brenner B: Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 262:854-861, 1992.
18. Bone R: Pathogenesis of sepsis. Ann Med 115:457-469, 1991.
19. Weitzberg E, Ahlborg G, Lundberg J: Differences in vascular effects and removal of ET-1 in human lung, brain and skeletal muscle. Clin Physiol 13:653-662, 1993.
20. Weitzberg E, Hemsén A, Rudehill A, Modin A, Wanecek M, Lundberg J: Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol 118:617-626, 1996.
21. Leeper Woodford S, Carey P, Byrne K, et al: Ibuprofen attenuates plasma tumor necrosis factor activity during sepsis-induced acute lung injury. J Appl Physiol 71:915-923, 1991.
22. Weitzberg E, Lundberg JM, Rudehill A: Inhibitory effects of diclofenac on the endotoxin shock response in relation to endothelin turnover in the pig. Acta Anaesthesiol Scand 39:50-59, 1995.
23. Bigatello L, Zapol M: New approaches to acute lung injury. Br J Anaesth 77:99-109, 1996.
24. Hernsen A: Biochemical and functional characterization of endothelin peptides with special references to vascular effects. Acta Physiol Scand 142:5-61, 1991.
25. Wagner OF, Christ G, Wojta J, et al: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068, 1992.
26. Steward D, Levy R, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 114:464-469, 1991.
27. Druml W, Steltzer H, Waldhausl W, et al: Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 148:1169-1173, 1993.
28. Ugiccioni M, Pulsatelli L, Grigolo B, et al: ET-1 in idiopathic pulmonary fibrosis. J Clin Pathol 48:330-334, 1995.
29. Wang Y, Coe Y, Toyoda O, Coceani F: Involvement of endothelin-1 in hypoxic pulmonary vasoconstriction in the lamb. J Physiol 482:421-434, 1995.
30. Helset E, Ytrehus K, Tveita T, Kjëve J, Jörgensen L: ET-1 causes accumulation of leukocytes in the pulmonary circulation. Circ Shock 44:201-209, 1994.
31. Korthuis RJ, Anderson DC, Granger DN: Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care 9:47-71, 1994.
32. 1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70:601-606, 1989.
33. Parillo J, Parker M, Natanson C, et al: Septic shock in humans. Ann Intern Med 113:227-242, 1990.
34. Vincent JL, Reuse C, Frank N, Contempre B, Kahn R: Right ventricular dysfunction in septic shock: Assessment by measurements of right ventricular ejection fraction using the thermodilution technique. Acta Anaesthesiol Scand 33:34-38, 1989.
35. Kiowski W, Sütsch G, Hunziker P, et al: Evidence of ET-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-736, 1995.
36. Ezra D, Goldstein R, Czaja J, Feuerstein G: Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol 257:H339-H343, 1989.
37. Klosterhalfen B, Horstmann-Jungemann K, Vogel P, et al: Time course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol. 43:2103-2109, 1992.
38. Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y: Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 38(Suppl 1):29-35, 1992.
39. Natanson C, Eichenholz PW, Danner RL, et al: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823-832, 1989.
40. Hemsén A, Modin A, Wanecek M, Malmström R, Weitzberg E: Effects of Ro-47-0203 and PD 155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig. Eur J Pharmacol 1997. In press.